Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06195319 · ClinicalTrials.gov registry record · Phase 1
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects
A Phase 1 study of Metabolism and Absorption, sponsored by Cassava Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06195319 is a Phase 1 study of Metabolism and Absorption that has completed, run by Cassava Sciences. The registered enrollment target is 8 participants, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06195319, a Phase 1 study of Metabolism and Absorption, has completed, sponsored by Cassava Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the absorption, metabolism, and excretion of \[14C\]-simufilam in healthy male subjects following a single oral administration of 100 mg of (approximately 100 µCi) \[14C\]-simufilam.
Conditions Studied
Interventions
- DRUG Simufilam
Study Locations (1)
Wisconsin
- Fortrea - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2024-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06195319
The ClinicalTrials.gov registry entry for NCT06195319 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The listed sponsor is Cassava Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metabolism appearing as the primary indexed condition, and to 1 intervention - of which Simufilam is the first listed.
NCT06195319 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06195319 about?
NCT06195319 is a clinical study titled "Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects". To evaluate the absorption, metabolism, and excretion of \[14C\]-simufilam in healthy male subjects following a single oral administration of 100 mg of (approximately 100 µCi) \[14C\]-simufilam.
What is the current status of trial NCT06195319?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-02-07. Estimated completion is 2024-03-27.
What conditions does trial NCT06195319 study?
This clinical trial studies the following conditions: Metabolism, Absorption, Excretion.
What interventions are being tested in trial NCT06195319?
The interventions under investigation include: Simufilam (DRUG).
Who is sponsoring clinical trial NCT06195319?
This trial is sponsored by Cassava Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06195319 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE
COMPLETED · Phase 1
-
Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females
COMPLETED · Phase 1
-
GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women
RECRUITING · NA
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants
RECRUITING
-
Caloric Balance Markers Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.